| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Zachary M Bush, Mary Lee Vanc. Management of acromegaly: is there a role for primary medical therapy? Reviews in endocrine & metabolic disorders. vol 9. issue 1. 2008-04-30. PMID:18163213. |
acromegaly is a chronic, debilitating disease caused by chronic growth hormone (gh) hypersecretion which results in chronic medical comorbidities, poor quality of life and high mortality rates. |
2008-04-30 |
2023-08-12 |
Not clear |
| Anelia Horvath, Constantine A Strataki. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Reviews in endocrine & metabolic disorders. vol 9. issue 1. 2008-04-30. PMID:18200440. |
acromegaly results from oversecretion of growth hormone (gh) by the proliferating somatotrophs. |
2008-04-30 |
2023-08-12 |
human |
| Rocio A Cordero, Ariel L Barka. Current diagnosis of acromegaly. Reviews in endocrine & metabolic disorders. vol 9. issue 1. 2008-04-30. PMID:18236162. |
acromegaly is a rare and chronic condition that is characterized by sustained unregulated hypersecretion of growth hormone (gh). |
2008-04-30 |
2023-08-12 |
Not clear |
| Ariel L Barka. Defining normalcy of the somatotropic axis: an attainable goal? Pituitary. vol 10. issue 2. 2008-04-17. PMID:17410470. |
the diagnoses of acromegaly and dwarfism require biochemical confirmation of abnormal gh and igf-1 concentrations. |
2008-04-17 |
2023-08-12 |
Not clear |
| David R Clemmon. IGF-I assays: current assay methodologies and their limitations. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17429590. |
the diagnosis of disorders of growth hormone (gh) is dependent upon accurate measurement of insulin-like growth factor-i (igf-i) concentrations since serum igf-i assays have been found to be useful as a screening tests for the presence of growth hormone deficiency (ghd) in children and in both children and adults they have been found very useful in establishing the diagnosis of acromegaly. |
2008-04-17 |
2023-08-12 |
human |
| David R Clemmon. IGF-I assays: current assay methodologies and their limitations. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17429590. |
igf-i is also used extensively to monitor the response to gh treatment in children and adults and to monitor the response to treatment in acromegaly. |
2008-04-17 |
2023-08-12 |
human |
| Martin Bidlingmaier, Christian J Strasburge. Growth hormone assays: current methodologies and their limitations. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17429592. |
an additional challenge arose from the availability of a gh receptor antagonist for the treatment of acromegaly, which is basically a mutated form of gh and therefore interferes in many gh assays. |
2008-04-17 |
2023-08-12 |
Not clear |
| Brian Roberts, Laurence Katznelso. Approach to the evaluation of the GH/IGF-axis in patients with pituitary disease: which test to order. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17429594. |
the diagnosis of adult growth hormone deficiency (aghd) and acromegaly involves assessment of serum growth hormone (gh) and insulin-like growth factor-1 (igf-1) concentrations. |
2008-04-17 |
2023-08-12 |
Not clear |
| Brian Roberts, Laurence Katznelso. Approach to the evaluation of the GH/IGF-axis in patients with pituitary disease: which test to order. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17429594. |
in patients with suspected acromegaly, the diagnosis is confirmed by elevated serum igf-1 levels and further validated by the presence of elevated gh levels both before and following an oral glucose load. |
2008-04-17 |
2023-08-12 |
Not clear |
| Brian Roberts, Laurence Katznelso. Approach to the evaluation of the GH/IGF-axis in patients with pituitary disease: which test to order. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17429594. |
a goal of acromegaly therapy is to normalize igf-1 concentrations, and, depending on the therapeutic modality, gh levels as well. |
2008-04-17 |
2023-08-12 |
Not clear |
| A M Brooke, W M Drak. Serum IGF-I levels in the diagnosis and monitoring of acromegaly. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17431794. |
insulin-like growth factor-i (igf-i) is a reliable marker of disease activity and growth hormone (gh) status in acromegaly, but its clinical utility has been hampered over the years by various issues including a lack of robust reference range data and variability in assay sensitivity and specificity. |
2008-04-17 |
2023-08-12 |
Not clear |
| A M Brooke, W M Drak. Serum IGF-I levels in the diagnosis and monitoring of acromegaly. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17431794. |
in acromegaly igf-i correlates well with gh activity and nadir gh on oral glucose tolerance test (ogtt) and is the most sensitive and specific test in diagnosis, where serum igf-i is persistently seen to be elevated to a range that is distinct from that in healthy individuals. |
2008-04-17 |
2023-08-12 |
Not clear |
| A M Brooke, W M Drak. Serum IGF-I levels in the diagnosis and monitoring of acromegaly. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17431794. |
successful medical or surgical treatment of acromegaly is usually associated with normalisation of serum igf-i but there is discordance between gh and igf-i in some patients. |
2008-04-17 |
2023-08-12 |
Not clear |
| A M Brooke, W M Drak. Serum IGF-I levels in the diagnosis and monitoring of acromegaly. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17431794. |
in contrast to the diagnosis of acromegaly, there is also considerable overlap in serum igf-i with normality after primary treatment of disease, even in the presence of persisting gh excess. |
2008-04-17 |
2023-08-12 |
Not clear |
| Akira Sata, Ken K Y H. Growth hormone measurements in the diagnosis and monitoring of acromegaly. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17458702. |
before the availability of immunoassays for igf-i, growth hormone (gh) measurement was the sole method used in the biochemical assessment of acromegaly. |
2008-04-17 |
2023-08-12 |
Not clear |
| Akira Sata, Ken K Y H. Growth hormone measurements in the diagnosis and monitoring of acromegaly. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17458702. |
the last 25 years has seen important advances in the understanding of the neuroregulation and in the characterization of gh secretion in acromegaly. |
2008-04-17 |
2023-08-12 |
Not clear |
| Akira Sata, Ken K Y H. Growth hormone measurements in the diagnosis and monitoring of acromegaly. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17458702. |
the availability of supersensitive gh has changed many aspects of the interpretation of gh-value in the management of acromegaly. |
2008-04-17 |
2023-08-12 |
Not clear |
| Akira Sata, Ken K Y H. Growth hormone measurements in the diagnosis and monitoring of acromegaly. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17458702. |
hypersecretion and abnormal neuroregulation characterize gh secretion in acromegaly. |
2008-04-17 |
2023-08-12 |
Not clear |
| Akira Sata, Ken K Y H. Growth hormone measurements in the diagnosis and monitoring of acromegaly. Pituitary. vol 10. issue 2. 2008-04-17. PMID:17458702. |
there is a place for measuring gh in the management of acromegaly although it complements that of igf-i. |
2008-04-17 |
2023-08-12 |
Not clear |
| Magdolna Kovács, Andrew V Schally, József L Varga, Márta Zaránd. Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists. Current medicinal chemistry. vol 15. issue 4. 2008-04-15. PMID:18288987. |
ghrh antagonists suppressed the release of gh and insulin-like growth factor (igf)-i in transgenic mice overexpressing human (h) ghrh gene, an animal model of human acromegaly. |
2008-04-15 |
2023-08-12 |
mouse |